390 related articles for article (PubMed ID: 33671562)
1. The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer's Disease and Parkinson's Disease.
Pawlik P; Błochowiak K
Diagnostics (Basel); 2021 Feb; 11(2):. PubMed ID: 33671562
[TBL] [Abstract][Full Text] [Related]
2. Salivary Biomarkers: Future Approaches for Early Diagnosis of Neurodegenerative Diseases.
Schepici G; Silvestro S; Trubiani O; Bramanti P; Mazzon E
Brain Sci; 2020 Apr; 10(4):. PubMed ID: 32326227
[TBL] [Abstract][Full Text] [Related]
3. Salivary levels of disease-related biomarkers in the early stages of Parkinson's and Alzheimer's disease:
Sabaei M; Rahimian S; Haj Mohamad Ebrahim Ketabforoush A; Rasoolijazi H; Zamani B; Hajiakhoundi F; Soleimani M; Shahidi G; Faramarzi M
IBRO Neurosci Rep; 2023 Jun; 14():285-292. PubMed ID: 36942319
[TBL] [Abstract][Full Text] [Related]
4. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients.
Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A
CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563
[TBL] [Abstract][Full Text] [Related]
6. Salivary Biomarkers for Alzheimer's Disease and Related Disorders.
Ashton NJ; Ide M; Zetterberg H; Blennow K
Neurol Ther; 2019 Dec; 8(Suppl 2):83-94. PubMed ID: 31833026
[TBL] [Abstract][Full Text] [Related]
7. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease.
Kang JH
J Mov Disord; 2016 May; 9(2):89-96. PubMed ID: 27240810
[TBL] [Abstract][Full Text] [Related]
9. Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease.
Farotti L; Paciotti S; Tasegian A; Eusebi P; Parnetti L
Expert Rev Mol Diagn; 2017 Aug; 17(8):771-780. PubMed ID: 28604235
[TBL] [Abstract][Full Text] [Related]
10. The potential roles of salivary biomarkers in neurodegenerative diseases.
Jiao LL; Dong HL; Liu MM; Wu PL; Cao Y; Zhang Y; Gao FG; Zhu HY
Neurobiol Dis; 2024 Apr; 193():106442. PubMed ID: 38382884
[TBL] [Abstract][Full Text] [Related]
11. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review on Saliva Biomarkers in Patients Diagnosed with Morbus Alzheimer and Morbus Parkinson.
Wolgin M; Zobernig M; Dvornyk V; Braun RJ; Kielbassa AM
Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35885007
[TBL] [Abstract][Full Text] [Related]
13. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
Williams SM; Schulz P; Sierks MR
Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
[TBL] [Abstract][Full Text] [Related]
14. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
[TBL] [Abstract][Full Text] [Related]
15. A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.
Kruse N; Schlossmacher MG; Schulz-Schaeffer WJ; Vanmechelen E; Vanderstichele H; El-Agnaf OM; Mollenhauer B
PLoS One; 2016; 11(4):e0153564. PubMed ID: 27116005
[TBL] [Abstract][Full Text] [Related]
16. Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer's Disease.
Omar SH; Preddy J
J Pers Med; 2020 Jul; 10(3):. PubMed ID: 32708853
[TBL] [Abstract][Full Text] [Related]
17. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
19. Modulation of Parkinson's Disease Associated Protein Rescues Alzheimer's Disease Degeneration.
Nunomura A; Zhu X; Perry G
J Alzheimers Dis; 2017; 55(1):73-75. PubMed ID: 27802241
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
